Amani Therapeutics
Latest round
- Series A
Last raised
- Mar 2026
Total raised
- $25M
Investors
- 1
About Amani Therapeutics
Amani Therapeutics, founded in 2025 in New York, US, is dedicated to addressing neuropsychiatric disorders through the development of advanced therapies.00 mn from RTW Investments.Amani Therapeutics specializes in developing innovative therapies for serious neuropsychiatric disorders, focusing on its lead product, AM-01. This therapy is a fixed-dose combination of clozapine and a novel chemical entity designed to maximize efficacy for treatment-resistant schizophrenia while reducing the risk of severe neutropenia. Revenue generation is expected through partnerships with healthcare institutions and distribution agreements with pharmaceutical wholesalers. The company is also looking to expand into international markets where treatment-resistant schizophrenia is prevalent, leveraging its collaborations to facilitate this growth.
Who invested in Amani Therapeutics
1 investor across 1 round
See all investors in Amani Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 23, 2026
Amount
$25M
Investors
Questions about Amani Therapeutics
Who invested in Amani Therapeutics?
Amani Therapeutics has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Amani Therapeutics raised?
Amani Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Amani Therapeutics last raise money?
Amani Therapeutics's most recent round on record is a Series A, in Mar 2026.
What does Amani Therapeutics do?
Amani Therapeutics, founded in 2025 in New York, US, is dedicated to addressing neuropsychiatric disorders through the development of advanced therapies.
Where is Amani Therapeutics headquartered?
Amani Therapeutics is headquartered in New York, US.
Which VCs invest in companies like Amani Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Amani Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Amani Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.